{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T17:50:45Z","timestamp":1785865845705,"version":"3.56.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T00:00:00Z","timestamp":1719532800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T00:00:00Z","timestamp":1719532800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82273267"],"award-info":[{"award-number":["82273267"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82173148"],"award-info":[{"award-number":["82173148"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073036"],"award-info":[{"award-number":["82073036"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell. Mol. Life Sci."],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Cetuximab resistance has been a major challenge for head and neck squamous cell carcinoma (HNSCC) patients receiving targeted therapy. However, the mechanism that causes cetuximab resistance, especially microRNA (miRNA) regulation, remains unclear. Growing evidence suggests that miRNAs may act as \u201cnuclear activating miRNAs\u201d for targeting promoter regions or enhancers related to target genes. This study elucidates a novel mechanism underlying cetuximab resistance in HNSCC involving the nuclear activation of KDM7A transcription via miR-451a. Herein, small RNA sequencing, quantitative real-time polymerase chain reaction (qRT\u2012PCR) and fluorescence in situ hybridization (FISH) results provided compelling evidence of miR-451a nuclear enrichment in response to cetuximab treatment. Chromatin isolation via RNA purification, microarray analysis, and bioinformatic analysis revealed that miR-451a interacts with an enhancer region in KDM7A, activating its expression and further facilitating cetuximab resistance. It has also been demonstrated that the activation of KDM7A by nuclear miR-451a is induced by cetuximab treatment and is AGO2 dependent. Logistic regression analyses of 87\u00a0HNSCC samples indicated the significance of miR-451a and KDM7A in the development of cetuximab resistance. These discoveries support the potential of miR-451a and KDM7A as valuable biomarkers for cetuximab resistance and emphasize the function of nuclear-activating miRNAs.<\/jats:p>\n                <jats:p><jats:bold>Graphical abstract<\/jats:bold><\/jats:p>","DOI":"10.1007\/s00018-024-05324-x","type":"journal-article","created":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T20:28:26Z","timestamp":1719606506000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Nuclear miR-451a activates KDM7A and leads to cetuximab resistance in head and neck squamous cell carcinoma"],"prefix":"10.1007","volume":"81","author":[{"given":"Peisong","family":"Zhai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoning","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuwen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayi","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8329-2357","authenticated-orcid":false,"given":"Jianjun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,28]]},"reference":[{"key":"5324_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"5324_CR2","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.semcancer.2018.01.008","volume":"52","author":"B Solomon","year":"2018","unstructured":"Solomon B, Young RJ, Rischin D (2018) Head and neck squamous cell carcinoma: genomics and emerging biomarkers for immunomodulatory cancer treatments. Semin Cancer Biol 52:228\u2013240. https:\/\/doi.org\/10.1016\/j.semcancer.2018.01.008","journal-title":"Semin Cancer Biol"},{"key":"5324_CR3","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1158\/1535-7163.MCT-17-0384","volume":"17","author":"HE Pearson","year":"2018","unstructured":"Pearson HE, Iida M, Orbuch RA et al (2018) Overcoming resistance to cetuximab with honokiol, a small-molecule polyphenol. Mol Cancer Ther 17:204\u2013214. https:\/\/doi.org\/10.1158\/1535-7163.MCT-17-0384","journal-title":"Mol Cancer Ther"},{"key":"5324_CR4","doi-asserted-by":"publisher","first-page":"e302","DOI":"10.1016\/S1470-2045(13)70085-8","volume":"14","author":"B Burtness","year":"2013","unstructured":"Burtness B, Bauman JE, Galloway T (2013) Novel targets in HPV-negative head and neck cancer: overcoming resistance to EGFR inhibition. Lancet Oncol 14:e302\u2013e309. https:\/\/doi.org\/10.1016\/S1470-2045(13)70085-8","journal-title":"Lancet Oncol"},{"key":"5324_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-00224-3","author":"DE Johnson","year":"2020","unstructured":"Johnson DE, Burtness B, Leemans CR et al (2020) Head and neck squamous cell carcinoma. Nat Rev Dis Prim. https:\/\/doi.org\/10.1038\/s41572-020-00224-3","journal-title":"Nat Rev Dis Prim"},{"key":"5324_CR6","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/S1470-2045(09)70311-0","volume":"11","author":"JA Bonner","year":"2010","unstructured":"Bonner JA, Harari PM, Giralt J et al (2010) Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomizedrandomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 11:21\u201328. https:\/\/doi.org\/10.1016\/S1470-2045(09)70311-0","journal-title":"Lancet Oncol"},{"key":"5324_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2021.103424","volume":"164","author":"E Muraro","year":"2021","unstructured":"Muraro E, Fanetti G, Lupato V et al (2021) Cetuximab in locally advanced head and neck squamous cell carcinoma: biological mechanisms involved in efficacy, toxicity and resistance. Crit Rev Oncol Hematol 164:103424. https:\/\/doi.org\/10.1016\/j.critrevonc.2021.103424","journal-title":"Crit Rev Oncol Hematol"},{"key":"5324_CR8","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1158\/1078-0432.CCR-09-2318","volume":"16","author":"LF Chen","year":"2010","unstructured":"Chen LF, Cohen EEW, Grandis JR (2010) New strategies in head and neck cancer: understanding resistance to epidermal growth factor receptor inhibitors. Clin Cancer Res 16:2489\u20132495. https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-2318","journal-title":"Clin Cancer Res"},{"key":"5324_CR9","doi-asserted-by":"publisher","first-page":"4331","DOI":"10.1158\/0008-5472.CAN-18-0459","volume":"78","author":"B Leonard","year":"2018","unstructured":"Leonard B, Brand TM, O\u2019Keefe RA et al (2018) BET inhibition overcomes receptor tyrosine kinase-mediated cetuximab resistance in HNSCC. Cancer Res 78:4331\u20134333. https:\/\/doi.org\/10.1158\/0008-5472.CAN-18-0459","journal-title":"Cancer Res"},{"key":"5324_CR10","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1200\/JCO.2009.24.6116","volume":"28","author":"A Bardelli","year":"2010","unstructured":"Bardelli A, Siena S (2010) Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol 28:1254\u20131261. https:\/\/doi.org\/10.1200\/JCO.2009.24.6116","journal-title":"J Clin Oncol"},{"key":"5324_CR11","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1200\/JCO.2005.08.037","volume":"23","author":"KY Chung","year":"2005","unstructured":"Chung KY, Shia J, Kemeny NE et al (2005) Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 23:1803\u20131810. https:\/\/doi.org\/10.1200\/JCO.2005.08.037","journal-title":"J Clin Oncol"},{"key":"5324_CR12","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1200\/JCO.2004.10.182","volume":"22","author":"LB Saltz","year":"2004","unstructured":"Saltz LB, Meropol NJ, Loehrer PJ et al (2004) Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22:1201\u20131208. https:\/\/doi.org\/10.1200\/JCO.2004.10.182","journal-title":"J Clin Oncol"},{"key":"5324_CR13","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/j.oraloncology.2012.06.016","volume":"48","author":"G Rabinowits","year":"2012","unstructured":"Rabinowits G, Haddad RI (2012) Overcoming resistance to EGFR inhibitor in head and neck cancer: a review of the literature. Oral Oncol 48:1085\u20131089. https:\/\/doi.org\/10.1016\/j.oraloncology.2012.06.016","journal-title":"Oral Oncol"},{"key":"5324_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12967-015-0633-7","volume":"13","author":"J Madoz-G\u00farpide","year":"2015","unstructured":"Madoz-G\u00farpide J, Zazo S, Chamizo C et al (2015) Activation of MET pathway predicts poor outcome to cetuximab in patients with recurrent or metastatic head and neck cancer. J Transl Med 13:1\u201313. https:\/\/doi.org\/10.1186\/s12967-015-0633-7","journal-title":"J Transl Med"},{"key":"5324_CR15","doi-asserted-by":"publisher","first-page":"8409","DOI":"10.7150\/thno.36605","volume":"9","author":"L Sun","year":"2019","unstructured":"Sun L, Fang Y, Wang X et al (2019) MiR-302a inhibits metastasis and cetuximab resistance in colorectal cancer by targeting NFIB and CD44. Theranostics 9:8409\u20138425. https:\/\/doi.org\/10.7150\/thno.36605","journal-title":"Theranostics"},{"key":"5324_CR16","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1038\/nm.4424","volume":"23","author":"Y Lu","year":"2017","unstructured":"Lu Y, Zhao X, Liu Q et al (2017) LncRNA MIR100HG-derived miR-100 and miR-125b mediate cetuximab resistance via Wnt\/\u03b2-catenin signaling. Nat Med 23:1331\u20131341. https:\/\/doi.org\/10.1038\/nm.4424","journal-title":"Nat Med"},{"key":"5324_CR17","doi-asserted-by":"publisher","DOI":"10.3892\/ijmm.2022.5148","author":"J Liu","year":"2022","unstructured":"Liu J, Yang T, Huang Z et al (2022) Transcriptional regulation of nuclear miRNAs in tumorigenesis (review). Int J Mol Med. https:\/\/doi.org\/10.3892\/ijmm.2022.5148","journal-title":"Int J Mol Med"},{"key":"5324_CR18","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/s0092-8674(04)00045-5","volume":"116","author":"DP Bartel","year":"2004","unstructured":"Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116:281\u2013297. https:\/\/doi.org\/10.1016\/s0092-8674(04)00045-5","journal-title":"Cell"},{"key":"5324_CR19","doi-asserted-by":"publisher","first-page":"7029","DOI":"10.1073\/pnas.111145798","volume":"98","author":"T Pestova","year":"2007","unstructured":"Pestova T, Kolupaeva V, Lomakin I et al (2007) Molecular mechanisms of translation initiation in eukaryotes. PNAS 98:7029\u20137036. https:\/\/doi.org\/10.1073\/pnas.111145798","journal-title":"PNAS"},{"key":"5324_CR20","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1038\/nature07299","volume":"455","author":"Y Tay","year":"2008","unstructured":"Tay Y, Zhang J, Thomson AM et al (2008) MicroRNAs to Nanog, Oct4 and Sox2 coding regions modulate embryonic stem cell differentiation. Nature 455:1124\u20131128. https:\/\/doi.org\/10.1038\/nature07299","journal-title":"Nature"},{"key":"5324_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4161\/rna.19354","volume":"9","author":"V Huang","year":"2012","unstructured":"Huang V, Long-Cheng L (2012) miRNA goes nuclear. RNA Biol 9:1\u20135","journal-title":"RNA Biol"},{"key":"5324_CR22","doi-asserted-by":"publisher","first-page":"5682","DOI":"10.1093\/nar\/gkr155","volume":"39","author":"ST Younger","year":"2011","unstructured":"Younger ST, Corey DR (2011) Transcriptional gene silencing in mammalian cells by miRNA mimics that target gene promoters. Nucleic Acids Res 39:5682\u20135691. https:\/\/doi.org\/10.1093\/nar\/gkr155","journal-title":"Nucleic Acids Res"},{"key":"5324_CR23","doi-asserted-by":"publisher","first-page":"E3325","DOI":"10.1073\/pnas.0707594105","volume":"105","author":"RF Place","year":"2018","unstructured":"Place RF, Li LC, Pookot D et al (2018) MicroRNA-373 induces expression of genes with complementary promoter sequences. Proc Natl Acad Sci U S A 105:E3325. https:\/\/doi.org\/10.1073\/pnas.0707594105","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5324_CR24","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1080\/15476286.2015.1112487","volume":"14","author":"M Xiao","year":"2017","unstructured":"Xiao M, Li J, Li W et al (2017) MicroRNAs activate gene transcription epigenetically as an enhancer trigger. RNA Biol 14:1326\u20131334. https:\/\/doi.org\/10.1080\/15476286.2015.1112487","journal-title":"RNA Biol"},{"key":"5324_CR25","doi-asserted-by":"publisher","first-page":"8556","DOI":"10.1093\/nar\/gkab626","volume":"49","author":"Y Liang","year":"2021","unstructured":"Liang Y, Lu Q, Li W et al (2021) Reactivation of tumour suppressor in breast cancer by enhancer switching through NamiRNA network. Nucleic Acids Res 49:8556\u20138572. https:\/\/doi.org\/10.1093\/nar\/gkab626","journal-title":"Nucleic Acids Res"},{"key":"5324_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0765-5","author":"H Liu","year":"2018","unstructured":"Liu H, Lei C, He Q et al (2018) Nuclear functions of mammalian MicroRNAs in gene regulation, immunity and cancer. Mol Cancer. https:\/\/doi.org\/10.1186\/s12943-018-0765-5","journal-title":"Mol Cancer"},{"key":"5324_CR27","doi-asserted-by":"publisher","first-page":"10086","DOI":"10.1093\/nar\/gkt777","volume":"41","author":"M Matsui","year":"2013","unstructured":"Matsui M, Chu Y, Zhang H et al (2013) Promoter RNA links transcriptional regulation of inflammatory pathway genes. Nucleic Acids Res 41:10086\u201310109. https:\/\/doi.org\/10.1093\/nar\/gkt777","journal-title":"Nucleic Acids Res"},{"key":"5324_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0160961","volume":"11","author":"MR Kang","year":"2016","unstructured":"Kang MR, Park KH, Yang JO et al (2016) miR-6734 Up-regulates p21 gene expression and induces cell cycle arrest and apoptosis in colon cancer cells. PLoS ONE 11:1\u201313. https:\/\/doi.org\/10.1371\/journal.pone.0160961","journal-title":"PLoS ONE"},{"key":"5324_CR29","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.1093\/hmg\/ddv018","volume":"24","author":"H Qu","year":"2015","unstructured":"Qu H, Zheng L, Pu J et al (2015) miRNA-558 promotes tumorigenesis and aggressiveness of neuroblastoma cells through activating the transcription of heparanase. Hum Mol Genet 24:2539\u20132551. https:\/\/doi.org\/10.1093\/hmg\/ddv018","journal-title":"Hum Mol Genet"},{"key":"5324_CR30","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1161\/CIRCRESAHA.119.314898","volume":"125","author":"H Li","year":"2019","unstructured":"Li H, Fan J, Zhao Y et al (2019) Nuclear miR-320 mediates diabetes-induced cardiac dysfunction by activating transcription of fatty acid metabolic genes to cause lipotoxicity in the heart. Circ Res 125:1106\u20131120. https:\/\/doi.org\/10.1161\/CIRCRESAHA.119.314898","journal-title":"Circ Res"},{"key":"5324_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/scd.2014.0290","volume":"00","author":"J Wang","year":"2014","unstructured":"Wang J, Huang V, Ye L et al (2014) Identification of small activating RNAs that enhance endogenous OCT4 expression. Stem Cells Dev 00:1\u20139. https:\/\/doi.org\/10.1089\/scd.2014.0290","journal-title":"Stem Cells Dev"},{"key":"5324_CR32","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/nchembio860","volume":"3","author":"BA Janowski","year":"2007","unstructured":"Janowski BA, Younger ST, Hardy DB et al (2007) Activating gene expression in mammalian cells with promoter-targeted duplex RNAs. Nat Chem Biol 3:166\u2013173. https:\/\/doi.org\/10.1038\/nchembio860","journal-title":"Nat Chem Biol"},{"key":"5324_CR33","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1038\/cr.2016.22","volume":"26","author":"V Portnoy","year":"2016","unstructured":"Portnoy V, Lin SHS, Li KH et al (2016) SaRNA-guided Ago2 targets the RITA complex to promoters to stimulate transcription. Cell Res 26:320\u2013335. https:\/\/doi.org\/10.1038\/cr.2016.22","journal-title":"Cell Res"},{"key":"5324_CR34","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.molcel.2011.08.027","volume":"44","author":"C Chu","year":"2011","unstructured":"Chu C, Qu K, Zhong FL et al (2011) Genomic maps of long noncoding rna occupancy reveal principles of RNA-chromatin interactions. Mol Cell 44:667\u2013678. https:\/\/doi.org\/10.1016\/j.molcel.2011.08.027","journal-title":"Mol Cell"},{"key":"5324_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22136721","author":"Y Bai","year":"2021","unstructured":"Bai Y, Pan B, Zhan X et al (2021) Microrna 195\u20135p targets foxo3 promoter region to regulate its expression in granulosa cells. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms22136721","journal-title":"Int J Mol Sci"},{"key":"5324_CR36","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.omtn.2019.11.006","volume":"19","author":"H Li","year":"2020","unstructured":"Li H, Zhan J, Zhao Y et al (2020) Identification of ncRNA-mediated functions of nucleus-localized mir-320 in cardiomyocytes. Mol Ther Nucleic Acids 19:132\u2013143. https:\/\/doi.org\/10.1016\/j.omtn.2019.11.006","journal-title":"Mol Ther Nucleic Acids"},{"key":"5324_CR37","doi-asserted-by":"publisher","first-page":"17337","DOI":"10.1073\/pnas.0607015103","volume":"103","author":"LC Li","year":"2006","unstructured":"Li LC, Okino ST, Zhao H et al (2006) Small dsRNAs induce transcriptional activation in human cells. Proc Natl Acad Sci U S A 103:17337\u201317342. https:\/\/doi.org\/10.1073\/pnas.0607015103","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5324_CR38","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.molcel.2021.11.005","volume":"82","author":"E Nazer","year":"2022","unstructured":"Nazer E, G\u00f3mez Acu\u00f1a L, Kornblihtt AR (2022) Seeking the truth behind the myth: argonaute tales from \u201cnuclearland.\u201d Mol Cell 82:503\u2013513. https:\/\/doi.org\/10.1016\/j.molcel.2021.11.005","journal-title":"Mol Cell"},{"key":"5324_CR39","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41416-020-0851-5","volume":"123","author":"LT Kagohara","year":"2020","unstructured":"Kagohara LT, Zamuner F, Davis-Marcisak EF et al (2020) Integrated single-cell and bulk gene expression and ATAC-seq reveals heterogeneity and early changes in pathways associated with resistance to cetuximab in HNSCC-sensitive cell lines. Br J Cancer 123:101\u2013113. https:\/\/doi.org\/10.1038\/s41416-020-0851-5","journal-title":"Br J Cancer"},{"key":"5324_CR40","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1038\/nature09092","volume":"465","author":"S Cheloufi","year":"2010","unstructured":"Cheloufi S, Dos Santos CO, Chong MMW, Hannon GJ (2010) A dicer-independent miRNA biogenesis pathway that requires Ago catalysis. Nature 465:584\u2013589. https:\/\/doi.org\/10.1038\/nature09092","journal-title":"Nature"},{"key":"5324_CR41","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.molcel.2020.02.020","volume":"78","author":"DA Kretov","year":"2020","unstructured":"Kretov DA, Walawalkar IA, Mora-Martin A et al (2020) Ago2-dependent processing allows miR-451 to evade the global microRNA turnover elicited during erythropoiesis. Mol Cell 78:317-328.e6. https:\/\/doi.org\/10.1016\/j.molcel.2020.02.020","journal-title":"Mol Cell"},{"key":"5324_CR42","first-page":"1","volume":"1","author":"PK Kakumani","year":"2023","unstructured":"Kakumani PK, Ko Y, Ramakrishna S et al (2023) CSDE1 promotes miR-451 biogenesis. Nucleic Acids Res 1:1\u201312","journal-title":"Nucleic Acids Res"},{"key":"5324_CR43","doi-asserted-by":"publisher","first-page":"208","DOI":"10.20892\/j.issn.2095-3941.2019.0153","volume":"17","author":"O Leblanc","year":"2020","unstructured":"Leblanc O, Vacher S, Lecerf C et al (2020) Biomarkers of cetuximab resistance in patients with head and neck squamous cell carcinoma. Cancer Biol Med 17:208\u2013217. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2019.0153","journal-title":"Cancer Biol Med"},{"key":"5324_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cells11010154","volume":"11","author":"INF Gomes","year":"2022","unstructured":"Gomes INF, da Silva-Oliveira RJ, da Silva LS et al (2022) Comprehensive molecular landscape of cetuximab resistance in head and neck cancer cell lines. Cells 11:1\u201320. https:\/\/doi.org\/10.3390\/cells11010154","journal-title":"Cells"},{"key":"5324_CR45","first-page":"454","volume":"10","author":"H Ju","year":"2020","unstructured":"Ju H, Hu Z, Lu Y et al (2020) TLR4 activation leads to anti-EGFR therapy resistance in HNSCC. Am J Cancer Res 10:454\u2013472","journal-title":"Am J Cancer Res"},{"key":"5324_CR46","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1158\/1535-7163.MCT-19-1036.Pathway-specific","volume":"19","author":"H Izumi","year":"2021","unstructured":"Izumi H, Wang Z, Goto Y et al (2021) Pathway-specific genome editing of PI3K\/mTOR tumor suppressor genes reveals that PTEN loss contributes to cetuximab resistance in head and neck cancer. Mol Cancer Ther 19:1562\u20131571. https:\/\/doi.org\/10.1158\/1535-7163.MCT-19-1036.Pathway-specific","journal-title":"Mol Cancer Ther"},{"key":"5324_CR47","doi-asserted-by":"publisher","first-page":"2933","DOI":"10.1158\/1078-0432.CCR-13-2721","volume":"20","author":"T Rampias","year":"2014","unstructured":"Rampias T, Giagini A, Siolos S et al (2014) RAS\/PI3K crosstalk and cetuximab resistance in head and neck squamous cell carcinoma. Clin Cancer Res 20:2933\u20132946. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-2721","journal-title":"Clin Cancer Res"},{"key":"5324_CR48","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.bbrc.2019.06.159","volume":"517","author":"CD Willey","year":"2019","unstructured":"Willey CD, Anderson JC, Trummell HQ et al (2019) Differential escape mechanisms in cetuximab-resistant head and neck cancer cells. Biochem Biophys Res Commun 517:36\u201342. https:\/\/doi.org\/10.1016\/j.bbrc.2019.06.159","journal-title":"Biochem Biophys Res Commun"},{"key":"5324_CR49","doi-asserted-by":"publisher","first-page":"3992","DOI":"10.1158\/0008-5472.CAN-06-0191","volume":"66","author":"A Li\u00e8vre","year":"2006","unstructured":"Li\u00e8vre A, Bachet JB, Le Corre D et al (2006) KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66:3992\u20133995. https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-0191","journal-title":"Cancer Res"},{"key":"5324_CR50","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-19-1036","author":"H Izumi","year":"2020","unstructured":"Izumi H, Wang Z, Goto Y et al (2020) Pathway-specific genome editing of PI3K \/ mTOR tumor suppressor genes reveals that PTEN loss contributes to cetuximab resistance in head and neck cancer. Mol Cancer Ther. https:\/\/doi.org\/10.1158\/1535-7163.MCT-19-1036","journal-title":"Mol Cancer Ther"},{"key":"5324_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-00908-0","author":"Y Yao","year":"2022","unstructured":"Yao Y, Wang Y, Chen L et al (2022) Clinical utility of PDX cohorts to reveal biomarkers of intrinsic resistance and clonal architecture changes underlying acquired resistance to cetuximab in HNSCC. Signal Transduct Target Ther. https:\/\/doi.org\/10.1038\/s41392-022-00908-0","journal-title":"Signal Transduct Target Ther"},{"key":"5324_CR52","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1016\/j.bjoms.2013.05.150","volume":"51","author":"T Cutilli","year":"2013","unstructured":"Cutilli T, Leocata P, Dolo V, Altobelli E (2013) Evaluation of p53 protein as a prognostic factor for oral cancer surgery. Br J Oral Maxillofac Surg 51:922\u2013927. https:\/\/doi.org\/10.1016\/j.bjoms.2013.05.150","journal-title":"Br J Oral Maxillofac Surg"},{"key":"5324_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers10100376","volume":"10","author":"S L\u00f3pez-Verd\u00edn","year":"2018","unstructured":"L\u00f3pez-Verd\u00edn S, Lavalle-Carrasco J, Carre\u00f3n-Burciaga RG et al (2018) Molecular markers of anticancer drug resistance in head and neck squamous cell carcinoma: a literature review. Cancers (Basel) 10:1\u201315. https:\/\/doi.org\/10.3390\/cancers10100376","journal-title":"Cancers (Basel)"},{"key":"5324_CR54","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1038\/nrgastro.2017.156","volume":"14","author":"H Thomas","year":"2017","unstructured":"Thomas H (2017) MiR-100 and miR-125b induce cetuximab resistance in CRC. Nat Rev Gastroenterol Hepatol 14:691. https:\/\/doi.org\/10.1038\/nrgastro.2017.156","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"5324_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-05536-8","author":"Q Zhang","year":"2023","unstructured":"Zhang Q, Zheng Y, Liu J et al (2023) CircIFNGR2 enhances proliferation and migration of CRC and induces cetuximab resistance by indirectly targeting KRAS via sponging to MiR-30b. Cell Death Dis. https:\/\/doi.org\/10.1038\/s41419-022-05536-8","journal-title":"Cell Death Dis"},{"key":"5324_CR56","doi-asserted-by":"publisher","first-page":"2712","DOI":"10.1002\/hed.26742","volume":"43","author":"S Yang","year":"2021","unstructured":"Yang S, Yuan ZJ, Zhu YH et al (2021) lncRNA PVT1 promotes cetuximab resistance of head and neck squamous cell carcinoma cells by inhibiting miR-124-3p. Head Neck 43:2712\u20132723. https:\/\/doi.org\/10.1002\/hed.26742","journal-title":"Head Neck"},{"key":"5324_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15252\/emmm.202012872","volume":"13","author":"F Citron","year":"2021","unstructured":"Citron F, Segatto I, Musco L et al (2021) miR-9 modulates and predicts the response to radiotherapy and EGFR inhibition in HNSCC. EMBO Mol Med 13:1\u201320. https:\/\/doi.org\/10.15252\/emmm.202012872","journal-title":"EMBO Mol Med"},{"key":"5324_CR58","doi-asserted-by":"publisher","first-page":"21716","DOI":"10.1002\/jcp.28888","volume":"234","author":"M Khordadmehr","year":"2019","unstructured":"Khordadmehr M, Jigari-Asl F, Ezzati H et al (2019) A comprehensive review on miR-451: a promising cancer biomarker with therapeutic potential. J Cell Physiol 234:21716\u201321731. https:\/\/doi.org\/10.1002\/jcp.28888","journal-title":"J Cell Physiol"},{"key":"5324_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2022.100412","volume":"33","author":"D Cao","year":"2022","unstructured":"Cao D, Ge S, Li M (2022) MiR-451a promotes cell growth, migration and EMT in osteosarcoma by regulating YTHDC1-mediated m6A methylation to activate the AKT\/mTOR signaling pathway. J Bone Oncol 33:100412. https:\/\/doi.org\/10.1016\/j.jbo.2022.100412","journal-title":"J Bone Oncol"},{"key":"5324_CR60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-022-01494-z","volume":"21","author":"R El Fatimy","year":"2022","unstructured":"El Fatimy R, Zhang Y, Deforzh E et al (2022) A nuclear function for an oncogenic microRNA as a modulator of snRNA and splicing. Mol Cancer 21:1\u201319. https:\/\/doi.org\/10.1186\/s12943-022-01494-z","journal-title":"Mol Cancer"},{"key":"5324_CR61","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1093\/carcin\/bgac102","volume":"44","author":"S Liu","year":"2023","unstructured":"Liu S, He X, Di Y et al (2023) NamiRNA-enhancer network of miR-492 activates the NR2C1-TGF-\u03b2\/Smad3 pathway to promote epithelial-mesenchymal transition of pancreatic cancer. Carcinogenesis 44:153\u2013165. https:\/\/doi.org\/10.1093\/carcin\/bgac102","journal-title":"Carcinogenesis"},{"key":"5324_CR62","doi-asserted-by":"publisher","DOI":"10.1261\/rna.034769.112","author":"K Nishi","year":"2013","unstructured":"Nishi K, Nishi A, Nagasawa T et al (2013) Human TNRC6A is an Argonaute-navigator protein for microRNA-mediated gene silencing in the nucleus Human TNRC6A is an Argonaute-navigator protein for microRNA-mediated gene silencing in the nucleus. RNA. https:\/\/doi.org\/10.1261\/rna.034769.112","journal-title":"RNA"},{"key":"5324_CR63","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1016\/j.celrep.2016.09.088","volume":"17","author":"S Katz","year":"2016","unstructured":"Katz S, Cussigh D, Urb\u00e1n N et al (2016) A nuclear role for miR-9 and argonaute proteins in balancing quiescent and activated neural stem cell states. Cell Rep 17:1383\u20131398. https:\/\/doi.org\/10.1016\/j.celrep.2016.09.088","journal-title":"Cell Rep"},{"key":"5324_CR64","doi-asserted-by":"publisher","first-page":"7447","DOI":"10.1093\/nar\/gkv705","volume":"43","author":"D Schraivogel","year":"2015","unstructured":"Schraivogel D, Schindler SG, Danner J et al (2015) Importin-\u03b2 facilitates nuclear import of human GW proteins and balances cytoplasmic gene silencing protein levels. Nucleic Acids Res 43:7447\u20137461. https:\/\/doi.org\/10.1093\/nar\/gkv705","journal-title":"Nucleic Acids Res"},{"key":"5324_CR65","doi-asserted-by":"publisher","first-page":"10270","DOI":"10.1074\/jbc.C113.541417","volume":"289","author":"Y Wei","year":"2014","unstructured":"Wei Y, Li L, Wang D et al (2014) Importin 8 regulates the transport of mature microRNAs into the cell nucleus. J Biol Chem 289:10270\u201310275. https:\/\/doi.org\/10.1074\/jbc.C113.541417","journal-title":"J Biol Chem"},{"key":"5324_CR66","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/nature12080","volume":"497","author":"J Shen","year":"2013","unstructured":"Shen J, Xia W, Khotskaya YB et al (2013) EGFR modulates microRNA maturation in response to hypoxia through phosphorylation of AGO2. Nature 497:383\u2013387. https:\/\/doi.org\/10.1038\/nature12080","journal-title":"Nature"},{"key":"5324_CR67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0189087","volume":"12","author":"K Dittmann","year":"2017","unstructured":"Dittmann K, Mayer C, Czemmel S et al (2017) New roles for nuclear EGFR in regulating the stability and translation of mRNAs associated with VEGF signaling. PLoS ONE 12:1\u201321","journal-title":"PLoS ONE"},{"key":"5324_CR68","doi-asserted-by":"publisher","first-page":"5658","DOI":"10.3390\/ijms21165658","volume":"21","author":"K-H Lee","year":"2020","unstructured":"Lee K-H, Kim B-C, Jeong S-H et al (2020) Histone demethylase KDM7A regulates androgen receptor activity, and its chemical inhibitor TC-E 5002 overcomes cisplatin-resistance in bladder cancer cells. Int J Mol Sci Artic 21:5658. https:\/\/doi.org\/10.3390\/ijms21165658","journal-title":"Int J Mol Sci Artic"},{"key":"5324_CR69","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1002\/ijc.31843","volume":"143","author":"K-H Lee","year":"2018","unstructured":"Lee K-H, Hong S, Kang M et al (2018) Histone demethylase KDM7A controls androgen receptor activity and tumor growth in prostate cancer. Int J Cancer 143:2849\u20132861. https:\/\/doi.org\/10.1002\/ijc.31843","journal-title":"Int J Cancer"},{"key":"5324_CR70","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1002\/jcp.29008","volume":"235","author":"Z Meng","year":"2020","unstructured":"Meng Z, Liu Y, Wang J et al (2020) Histone demethylase KDM7A is required for stem cell maintenance and apoptosis inhibition in breast cancer. J Cell Physiol 235:932\u2013943. https:\/\/doi.org\/10.1002\/jcp.29008","journal-title":"J Cell Physiol"}],"container-title":["Cellular and Molecular Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-024-05324-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00018-024-05324-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-024-05324-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T20:36:46Z","timestamp":1719607006000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00018-024-05324-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,28]]},"references-count":70,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["5324"],"URL":"https:\/\/doi.org\/10.1007\/s00018-024-05324-x","relation":{},"ISSN":["1420-682X","1420-9071"],"issn-type":[{"value":"1420-682X","type":"print"},{"value":"1420-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,28]]},"assertion":[{"value":"30 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or nonfinancial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All analyses and experiments we conducted using patient-derived tumour specimens were in accordance with the Declaration of Helsinki and approved by the ethics committee of Ninth People\u2019s Hospital Affiliated with Shanghai Jiao Tong University School of Medicine (approval no. SH9H-2023-T284-1). All animal experiments were approved by the Laboratory Animal Ethics Committee of the Ninth People's Hospital Affiliated with Shanghai Jiao Tong University School of Medicine and were performed in accordance with the relevant provisions of the National Experimental Animal Welfare Ethics (approval no.: SH9H-2023-A854-1).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All authors reviewed the results and contributed to the final manuscript. All authors approved this manuscript for publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The data that support the findings of this study are available within the article and its supplementary materials.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Microarray, small RNA sequencing and ChIRP-seq data generated from this study have been deposited in the Gene Expression Omnibus (GEO accession numbers GSE245159 and GSE244948 and GSE245153, respectively). Additional data are available from the corresponding author upon request.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability statement"}}],"article-number":"282"}}